Vidofludimus

N/A

Report date: 2024/09/18 10:05:27
NME

Base Information

Drug NameVidofludimus
Drug Alias Name维多莫司vidofludimusumVidofludimus calciumVidoCaSC-12267 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInterleukin 17A inhibitorsInterferon gamma inhibitorsDihydroorotate dehydrogenase inhibitors
TargetsDihydroorotate dehydrogenaseInterferon gammaInterleukin 17A
Therapy Area/IndicationsInflammatory Bowel DiseasesArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaPoland +[5] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator Companies4sc Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive Companies4sc Ag
Active IndicationsN/A
Inactive IndicationsInflammatory Bowel DiseasesArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A